KK8398
Phase 3Small molecule
Kyowa Kirin Co., Ltd.KK8398 is one of 13 small molecule programs targeting Achondroplasia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Achondroplasia
#DrugCompanyPhaseTrials
1Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Approved
BMN 333
BioMarin PharmaceuticalPhase 3
Voxzogo
BioMarin PharmaceuticalPhase 2
Truseltiq
HHelsinn Healthcare SA
Phase 2
TYRA-300
TTyra Biosciences, Inc
Phase 2
KK8398
Kyowa Kirin Co., Ltd.Phase 3
Yuviwel
Ascendis PharmaPhase 2
SAR442501
SanofiPhase 2
Recifercept
PfizerPhase 2
Infigratinib /kg
QQED Therapeutics, a BridgeBio company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KK8398. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company